# OnCo record benmelstobart (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/benmelstobart/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "benmelstobart" ;
  schema:name "Benmelstobart"@en ;
  schema:description "Benmelstobart is Chia Tai Tianqing's PD-L1 antibody, approved in China in 2024 for extensive-stage small-cell lung cancer in combination with anlotinib and chemotherapy."@en ;
  schema:url <https://onco.cc/drugs/benmelstobart/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=TQB2450> ;
  onco:status "approved" ;
  onco:tag "china", "nmpa-approved" ;
  onco:modality "Anti-PD-L1 monoclonal antibody" ;
  onco:approval "CN 2024: Extensive-stage small-cell lung cancer, first line, with anlotinib and platinum-etoposide chemotherapy" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:companies <https://onco.cc/companies/sino-biopharm/> .